On October 14, 2026, Pulse Biosciences, Inc. announced a significant partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. This collaboration focuses on the clinical utility of Pulse Biosciences' proprietary nPulse Vybrance Percutaneous Electrode System. The partnership is designed to enhance patient care and generate additional clinical data regarding the treatment of benign thyroid nodules.
Pulse Biosciences, a company specializing in surgical and medical instruments, is leveraging its innovative technology to improve treatment options in the healthcare sector. The nPulse Vybrance System utilizes nanosecond pulsed field ablation (nsPFA) technology, which delivers ultra-short bursts of electrical energy to cells, providing a nonthermal treatment option that minimizes risks associated with traditional surgical procedures.
Company Overview
Pulse Biosciences, Inc. operates within the surgical and medical instruments and apparatus sector, classified under SIC 3841. The company is publicly traded on the Nasdaq under the ticker symbol PLSE. Based in Hayward, California, Pulse Biosciences focuses on innovative bioelectric medicine solutions aimed at improving patient outcomes.
Details from the Filing
The recent SEC filing, accession number 0001437749-26-032601, outlines the partnership agreements established with the Clayman Thyroid Center. This collaboration includes both commercial and clinical components, allowing the center to utilize the nPulse Vybrance System in treating patients. The center will also engage in collecting real-world outcomes and conducting formal clinical studies to evaluate the effectiveness of nsPFA energy for treating benign thyroid nodules.
According to the filing, "The Clayman Thyroid Center is now treating patients with the Vybrance System as part of the controlled market development strategy." This partnership positions Pulse Biosciences to expand its reach and enhance the adoption of its innovative technology in a high-volume clinical setting.
Impact of the Partnership
This partnership may significantly impact patients suffering from benign thyroid nodules, providing them with access to advanced treatment options that are less invasive than traditional surgery. Furthermore, the collaboration with a reputable institution like the Clayman Thyroid Center could enhance the credibility of Pulse Biosciences' technology, potentially leading to broader acceptance and use in the medical community.
As the partnership progresses, it may also influence competitors in the surgical and medical instruments sector, prompting them to enhance their offerings or explore similar collaborations to remain competitive.
What's Next?
The filing does not specify what happens next, but the partnership's success will likely depend on the clinical outcomes and data generated from the studies conducted at the Clayman Thyroid Center. Pulse Biosciences is expected to continue developing its nPulse technology and may announce further updates as the partnership evolves.